FLOW analysis finds semaglutide safety consistent across kidney function strata

The wire

1. 01In the 3,533-participant FLOW trial, serious adverse events occurred in 45.1% on semaglutide 1.0 mg versus 50.4% on placebo at eGFR 60 or above, and 56.4% versus 60.4% below eGFR 30.
2. 02For clinicians treating type 2 diabetes with chronic kidney disease, the prespecified secondary analysis found no unexpected safety signals as eGFR fell, with adverse events of special interest similar between arms.
3. 03Discontinuations for gastrointestinal adverse events were 4.5% on semaglutide versus 1.1% on placebo; safety data were collected selectively and reported descriptively, not inferentially.

From the source

Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial

Kidney international · 2026 Oct 20 · Tuttle KR, Andersen MR, Arici M et al.